PURPOSE: To evaluate how the association between body size and breast cancer risk varies by tumor receptor subtype, host factors, and other exposures among women in the California Teachers Study cohort. METHODS: Among 52,642 postmenopausal women, 2,321 developed invasive breast cancer with known estrogen- and progesterone-receptor status (1,652 ER+PR+, 338 ER+PR-, and 312 ER-PR-) between 1995 and 2007. In a subset of 35,529 with waist circumference data, 1,377 developed invasive breast cancer with known ERPR status (991 ER+PR+, 208 ER+PR-, 169 ER-PR-) between 1997 and 2007. Multivariate Cox regression was performed to estimate relative risks (RR) and 95% confidence intervals (CI). RESULTS: Obesity, adult weight gain of ≥40 pounds, greater abdominal adiposity, and greater height increased the risk of ER+PR+ breast cancer. The increased risk associated with postmenopausal obesity was limited to those who did not use hormone therapy (HT) at cohort entry (RR = 1.37; 95% CI, 1.05-1.78 for BMI ≥ 30 vs. < 25 kg/m(2); p-interaction = 0.14) and those who were not overweight or obese at age 18 (p-interaction = 0.06). The increased risk associated with greater abdominal adiposity was limited to those who were not also overweight or obese (p-interaction = 0.01). Neither obesity, abdominal adiposity, nor height was associated with the risk of ER-PR- tumors. CONCLUSIONS: The effects of body size on postmenopausal breast cancer risk differed by hormone receptor subtype, and among women with ER+PR+ tumors, by HT use and early adult body size.
PURPOSE: To evaluate how the association between body size and breast cancer risk varies by tumor receptor subtype, host factors, and other exposures among women in the California Teachers Study cohort. METHODS: Among 52,642 postmenopausal women, 2,321 developed invasive breast cancer with known estrogen- and progesterone-receptor status (1,652 ER+PR+, 338 ER+PR-, and 312 ER-PR-) between 1995 and 2007. In a subset of 35,529 with waist circumference data, 1,377 developed invasive breast cancer with known ERPR status (991 ER+PR+, 208 ER+PR-, 169 ER-PR-) between 1997 and 2007. Multivariate Cox regression was performed to estimate relative risks (RR) and 95% confidence intervals (CI). RESULTS: Obesity, adult weight gain of ≥40 pounds, greater abdominal adiposity, and greater height increased the risk of ER+PR+ breast cancer. The increased risk associated with postmenopausal obesity was limited to those who did not use hormone therapy (HT) at cohort entry (RR = 1.37; 95% CI, 1.05-1.78 for BMI ≥ 30 vs. < 25 kg/m(2); p-interaction = 0.14) and those who were not overweight or obese at age 18 (p-interaction = 0.06). The increased risk associated with greater abdominal adiposity was limited to those who were not also overweight or obese (p-interaction = 0.01). Neither obesity, abdominal adiposity, nor height was associated with the risk of ER-PR- tumors. CONCLUSIONS: The effects of body size on postmenopausal breast cancer risk differed by hormone receptor subtype, and among women with ER+PR+ tumors, by HT use and early adult body size.
Authors: Huiyan Ma; Yaping Wang; Jane Sullivan-Halley; Linda Weiss; Ronald T Burkman; Michael S Simon; Kathleen E Malone; Brian L Strom; Giske Ursin; Polly A Marchbanks; Jill A McDonald; Robert Spirtas; Michael F Press; Leslie Bernstein Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08 Impact factor: 4.254
Authors: A Trentham-Dietz; P A Newcomb; K M Egan; L Titus-Ernstoff; J A Baron; B E Storer; M Stampfer; W C Willett Journal: Cancer Causes Control Date: 2000-07 Impact factor: 2.506
Authors: Z Huang; W C Willett; G A Colditz; D J Hunter; J E Manson; B Rosner; F E Speizer; S E Hankinson Journal: Am J Epidemiol Date: 1999-12-15 Impact factor: 4.897
Authors: Rachael T Leon Guerrero; Rachel Novotny; Lynne R Wilkens; Marie Chong; Kami K White; Yurii B Shvetsov; Arielle Buyum; Grazyna Badowski; Michelle Blas-Laguaña Journal: Cancer Epidemiol Date: 2017-10 Impact factor: 2.984
Authors: Henry M Kuerer; Sara A Lari; Banu K Arun; Chung-Yuan Hu; Abenaa Brewster; Elizabeth A Mittendorf; Constance T Albarracin; Gildy V Babiera; Abigail S Caudle; Jamie L Wagner; Jennifer K Litton; Isabelle Bedrosian; Funda Meric-Bernstam; Anthony Lucci; Kelly K Hunt Journal: Breast Cancer Res Treat Date: 2012-03-04 Impact factor: 4.872
Authors: Melanie Ruszczyk; Gary Zirpoli; Shicha Kumar; Elisa V Bandera; Dana H Bovbjerg; Lina Jandorf; Thaer Khoury; Helena Hwang; Gregory Ciupak; Karen Pawlish; Pepper Schedin; Patricia Masso-Welch; Christine B Ambrosone; Chi-Chen Hong Journal: Cancer Causes Control Date: 2015-11-30 Impact factor: 2.506
Authors: Esther M John; Meera Sangaramoorthy; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Anna R Giuliano; Roger K Wolff; Martha L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-28 Impact factor: 4.254
Authors: James R Cerhan; Steven C Moore; Eric J Jacobs; Cari M Kitahara; Philip S Rosenberg; Hans-Olov Adami; Jon O Ebbert; Dallas R English; Susan M Gapstur; Graham G Giles; Pamela L Horn-Ross; Yikyung Park; Alpa V Patel; Kim Robien; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Patricia Hartge; Leslie Bernstein; Amy Berrington de Gonzalez Journal: Mayo Clin Proc Date: 2014-03 Impact factor: 7.616
Authors: Avonne E Connor; Richard N Baumgartner; Dongyan Yang; Martha L Slattery; Anna R Giuliano; Betsy C Risendal; Madiha M Abdel-Maksoud; Kathy B Baumgartner Journal: Ann Epidemiol Date: 2013-01-28 Impact factor: 3.797